

Center for Drug Evaluation and Research (CDER)
Food and Drug Administration
Department of Health and Human Services

**Generic Drug User Fee Amendments of 2012 Regulatory Science Initiatives:
Request for Public Input for FY 2016 Generic Drug Research
Part 15 Public Hearing**

Panel Members

Kathleen “Cook” Uhl, M.D.

Director
Office of Generic Drugs, CDER

Robert Lionberger, Ph.D.

Director
Office of Research and Standards
Office of Generic Drugs, CDER

Dale Conner, PharmD

Deputy Director (acting)
Office of Bioequivalence
Office of Generic Drugs, CDER

Carol A. Holquist, RPh

Deputy Director (acting)
Office of Regulatory Operations
Office of Generic Drugs, CDER

Maryll Toufanian, J.D.

Deputy Director
Office of Generic Drug Policy
Office of Generic Drugs, CDER

Rick Friedman, M.S.

Deputy Director
Science & Regulatory Policy
Office of Manufacturing Quality
Office of Compliance, CDER

Ruth Barratt, PhD., DVM

Science Advisor
Office of Translational Sciences, CDER

Cindy Buhse, Ph.D.

Director
Office of Testing and Research
Office of Pharmaceutical Quality, CDER

Ashley Boam, MSBE

Director (acting)
Office of Policy for Pharmaceutical Quality
Office of Pharmaceutical Quality, CDER

Cindy Kortepeter, Pharm.D.

Deputy Director
Division of Pharmacovigilance I
Office of Surveillance and Epidemiology, CDER

Simone P Pinheiro, ScD MSc ALM

Associate Director for Epidemiology
Division of Epidemiology-I
Office of Surveillance and Epidemiology, CDER

Gisa Perez, MBA

Generics Branch Chief
Division of User Fee Management and Budget Formulation
Office of Management, CDER

Brenda Stodart, PharmD

Program Director
CDER Small Business and Industry Assistance Program
Division of Drug Information
Office of Communications, CDER